Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol
Background Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/8/e048168.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136641743224832 |
|---|---|
| author | Lamprini Syrogiannouli Martin Feller Nathalie Schwab Nicolas Rodondi Arnaud Chiolero Cinzia Del Giovane Douglas C Bauer Viktoria Gastens Daniela Anker |
| author_facet | Lamprini Syrogiannouli Martin Feller Nathalie Schwab Nicolas Rodondi Arnaud Chiolero Cinzia Del Giovane Douglas C Bauer Viktoria Gastens Daniela Anker |
| author_sort | Lamprini Syrogiannouli |
| collection | DOAJ |
| description | Background Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to the estimated LE, there is no tool to estimate LE in this specific population. Our objective is therefore to develop an LE estimator for older multimorbid adults by transforming a mortality prognostic index, which will be developed and internally validated in a prospective cohort.Methods and analysis We will analyse data of the Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People cohort study in Bern, Switzerland. 822 participants were included at hospitalisation with age of 70 years or older, multimorbidity (three or more chronic medical conditions) and polypharmacy (use of five drugs or more for >30 days). All-cause mortality will be assessed during 3 years of follow-up. We will apply a flexible parametric survival model with backward stepwise selection to identify the mortality risk predictors. The model will be internally validated using bootstrapping techniques. We will derive a point-based risk score from the regression coefficients. We will transform the 3-year mortality prognostic index into an LE estimator using the Gompertz survival function. We will perform a qualitative assessment of the clinical usability of the LE estimator and its application. We will conduct the development and validation of the mortality prognostic index following the Prognosis Research Strategy (PROGRESS) framework and report it following the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement.Ethics and dissemination Written informed consent by patients themselves or, in the case of cognitive impairment, by a legal representative, was required before enrolment. The local ethics committee (Kantonale Ethikkommission Bern) has approved the study. We plan to publish the results in peer-reviewed journals and present them at national and international conferences. |
| format | Article |
| id | doaj-art-db61a8b81ccf40e79cb8d3d083ba8049 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-db61a8b81ccf40e79cb8d3d083ba80492024-12-09T00:35:07ZengBMJ Publishing GroupBMJ Open2044-60552021-08-0111810.1136/bmjopen-2020-048168Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocolLamprini Syrogiannouli0Martin Feller1Nathalie Schwab2Nicolas Rodondi3Arnaud Chiolero4Cinzia Del Giovane5Douglas C Bauer6Viktoria Gastens7Daniela Anker8Institute of Primary Health Care (BIHAM), University of Bern, Bern, SwitzerlandInstitute of Primary Health Care (BIHAM), University of Bern, Bern, SwitzerlandDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandInstitute of Primary Health Care, University of Bern, Bern, SwitzerlandPopulation Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, SwitzerlandInstitute of Primary Health Care (BIHAM), University of Bern, Bern, SwitzerlandprofessorInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerlandpostdoctoral research fellow and epidemiologistBackground Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to the estimated LE, there is no tool to estimate LE in this specific population. Our objective is therefore to develop an LE estimator for older multimorbid adults by transforming a mortality prognostic index, which will be developed and internally validated in a prospective cohort.Methods and analysis We will analyse data of the Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People cohort study in Bern, Switzerland. 822 participants were included at hospitalisation with age of 70 years or older, multimorbidity (three or more chronic medical conditions) and polypharmacy (use of five drugs or more for >30 days). All-cause mortality will be assessed during 3 years of follow-up. We will apply a flexible parametric survival model with backward stepwise selection to identify the mortality risk predictors. The model will be internally validated using bootstrapping techniques. We will derive a point-based risk score from the regression coefficients. We will transform the 3-year mortality prognostic index into an LE estimator using the Gompertz survival function. We will perform a qualitative assessment of the clinical usability of the LE estimator and its application. We will conduct the development and validation of the mortality prognostic index following the Prognosis Research Strategy (PROGRESS) framework and report it following the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement.Ethics and dissemination Written informed consent by patients themselves or, in the case of cognitive impairment, by a legal representative, was required before enrolment. The local ethics committee (Kantonale Ethikkommission Bern) has approved the study. We plan to publish the results in peer-reviewed journals and present them at national and international conferences.https://bmjopen.bmj.com/content/11/8/e048168.full |
| spellingShingle | Lamprini Syrogiannouli Martin Feller Nathalie Schwab Nicolas Rodondi Arnaud Chiolero Cinzia Del Giovane Douglas C Bauer Viktoria Gastens Daniela Anker Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol BMJ Open |
| title | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
| title_full | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
| title_fullStr | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
| title_full_unstemmed | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
| title_short | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
| title_sort | development and validation of a life expectancy estimator for multimorbid older adults a cohort study protocol |
| url | https://bmjopen.bmj.com/content/11/8/e048168.full |
| work_keys_str_mv | AT lamprinisyrogiannouli developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT martinfeller developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT nathalieschwab developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT nicolasrodondi developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT arnaudchiolero developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT cinziadelgiovane developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT douglascbauer developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT viktoriagastens developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT danielaanker developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol |